Navigation Links
First Patients Treated in Italy With the Percutaneous MitraClip(R) System
Date:10/21/2008

Use of the MitraClip System Expands in the European Union

MENLO PARK, Calif., Oct. 21 /PRNewswire/ -- Evalve, Inc., the leader in the development of devices for the percutaneous repair of cardiac valves, announced today that the first two patients in Italy have been treated with the MitraClip(R) system at Ferrarotto Hospital in Catania, Italy. The MitraClip system is the first commercially available medical device which provides a non-surgical mitral valve repair option for patients suffering from the effects of mitral regurgitation (MR).

MR is the second most common type of heart valve insufficiency in Europe, and the most common in the United States, affecting millions of people worldwide. Both in Europe and the United States, the vast majority of patients are untreated, which leaves their hearts affected by the chronic volume overload caused by MR, requiring the heart to work harder, and ultimately leading to heart failure.

The first patients in Italy were treated by the team led by Corrado Tamburino, M.D., Gian Paolo Ussia, M.D., Salvatore Scandura, M.D., and Sarah Mangiafico, M.D. at the University of Catania in Sicily, Italy.

"The MitraClip is a new option for high risk patients as well as patients who are not willing to undergo the standard surgical treatment for mitral insufficiency," said Prof. Corrado Tamburino, chair of cardiology, cardiology department, cardiac catheterization and interventional cardiology, Ferrarotto Hospital, University of Catania, Sicily. "I hope that this technique will be broadly adopted to treat suitable patients requiring a correction of mitral regurgitation."

"The procedural efficacy of the MitraClip system is enhanced by the ability to reposition the clip to achieve an optimum result," said Gian Paolo Ussia, M.D., director of the interventional structural and congenital heart disease program, Ferrarotto Hospital, University of Catania, Sicily. "I believe this technique can be safely
'/>"/>

SOURCE Evalve, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related medicine news :

1. Head-First Slide a Heads-Up Play
2. Tomophase to Exhibit First In-vivo Cross-sectional Images of Pulmonary Stenting Using Proprietary OCT System
3. Save Lives with Your Mobile Phone - Doctor Releases First Aid Application for iPhone
4. Lincare Holdings Inc. Announces Third Quarter and First Nine Months 2008 Financial Results
5. Samplify Systems Announces Availability of Worlds First 16-channel, 12-bit, 65 Msps A/D Converter With Integrated Real-Time Data Compression
6. US Oncologys Innovent Oncology Division Announces First Agreement Between Rocky Mountain Cancer Centers and Colorado Public Employees Retirement Association
7. American Well Systems CEO Roy Schoenberg to Present Live Public Demo of First Online Care Service at Health 2.0 Conference
8. Caltech engineers build first-ever multi-input plug-and-play synthetic RNA device
9. Mars First Confectionery Company to Launch Front-of-Pack Nutrition Labeling Globally
10. Integrated Medical Systems Receives FDA Clearance for Worlds First Suitcase Intensive Care Unit
11. Accuray Incorporated to Report First Quarter Fiscal Year 2009 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/22/2013)... these findings in the current online edition of ... study could open up new possibilities of early ... tackle diseases before the patient,s nervous system is ... of genetic diseases of the cerebellum and other ... limited control of their muscles. They also suffer ...
(Date:5/22/2013)... baby to finish the last ounce in their bottle might ... soon burn off, a bad habit remains. , Brigham Young ... clinical obesity at 24 months of age strongly traces back ... two, it puts you on a trajectory where you are ... as an adult," said Forste. "That,s a big concern." , ...
(Date:5/22/2013)... May 22, 2013 College and ... access to Adapt Courseware’s new Introduction to ... adaptive framework that responds based on each student’s ... the provider of comprehensive adaptive online curriculum resources ... to develop introductory level general education offerings, enabling ...
(Date:5/22/2013)... 22, 2013 Officials with Alliance Commercial ... cicada services are now in full effect due to ... cicada cycle emerges. , “The cicada emerges in ... they will emerge, so we’re now offering services to ... protected during the invasion,” said R. Brett Madden, Esq., ...
(Date:5/22/2013)... (PRWEB) May 22, 2013 According to ... an autoimmune disorder effecting up to 3 million people ... damage to the small intestine and mal-absorption of nutrients(2). ... as diarrhea, constipation, weight loss and vitamin deficiency, people ... While there are many gluten-free foods that celiac sufferers ...
Breaking Medicine News(10 mins):Health News:A pan-European study: Signs of motor disorders can appear years before disease manifestation 2Health News:A pan-European study: Signs of motor disorders can appear years before disease manifestation 3Health News:Overeating learned in infancy, study suggests 2Health News:Adapt Courseware Releases Introduction to Sociology for Colleges and Universities Nationwide 2Health News:Adapt Courseware Releases Introduction to Sociology for Colleges and Universities Nationwide 3Health News:Alliance Commercial Pest Control, Inc. Now Offering Cicada Protection Services 2Health News:During Celiac Awareness Month, Nutrition Expert Keri Glassman Encourages People with Celiac Disease to Find a Fiber Alternative like Konsyl Original Formula 2Health News:During Celiac Awareness Month, Nutrition Expert Keri Glassman Encourages People with Celiac Disease to Find a Fiber Alternative like Konsyl Original Formula 3
... troubles ,the day after, and protect liver from damage, experts ... a hangover, drink lots of water, get plenty of rest ... study shows that the amino acids and minerals in asparagus ... toxins in alcohol. , Researchers at the Institute of Medical ...
... a technique widely used in studying the human brain. ... signals are generated at brain cell level. This information ... from the Academy of Finland,s Neuroscience Research Programme (NEURO) ... play a key role in the generation of fMRI ...
... and the University of Pittsburgh Medical Center will be ... conjunction with the G20 Pittsburgh Summit Sept. 24-25. These ... how and why the "eds and meds" sector of ... region,s success. The Eds-Meds program will begin at ...
... , RUTHERFORD, N.J., Aug. 28 As ... to soar, and sales and profits are being diverted ... commitment to keep their Vectra(R) products, and the health ... professionals. Through their Bloodhound(R) Technology, a unique track-and-trace barcode ...
... MUMBAI, India, Aug. 28 Sun Pharmaceutical Industries Ltd. (Reuters: ... announced that on August 27, 2009, Sun filed a new ... Antitrust Division of the U.S. Department of Justice to restart ... Tender Offer by Alkaloida Chemical Company Exclusive Group Ltd. (Alkaloida), ...
... someday aid in understanding ADD and more , FRIDAY, Aug. ... in a crowd, it appears that your "mind,s eye" acts ... you until you find the right person. , Researchers from ... monkeys as they searched for a specific tilted, colored bar ...
Cached Medicine News:Health News:Asparagus May Ease Hangover 2Health News:New research findings pave the way to more accurate interpretation of brain imaging data 2Health News:Summit VetPharm Helps Veterinarians Protect Against Product Diversion, Counterfeiting and Shrinkage Using Vectra(R) Bloodhound(R) Technology 2Health News:Summit VetPharm Helps Veterinarians Protect Against Product Diversion, Counterfeiting and Shrinkage Using Vectra(R) Bloodhound(R) Technology 3Health News:Sun Pharmaceutical Files HSR Application for Taro Tender Offer 2Health News:Sun Pharmaceutical Files HSR Application for Taro Tender Offer 3Health News:Brain May Use Its 'Mind's Eye' to Control Chaos 2
(Date:5/22/2013)... Mass. and TORONTO , ... ) (OTCBB: GNBT) today announced three presentations demonstrating the ... by its wholly-owned subsidiary, Antigen Express, Inc. ( www.antigenexpress.com ... meeting of the American Society of Clinical Oncology (ASCO) ... from May 31 through June 4, 2013. ...
(Date:5/22/2013)...  Grifols, ein globales Unternehmen der Gesundheitsbranche ... , Spanien, präsentierte die Ergebnisse einer Studie, ... PROLASTIN©-C (Alpha1-Proteinasehemmer [human]) den Spiegel des Alpha1-Proteins ... Niveau anhebt, das innerhalb des für gesunde ... eine lebensbedrohliche, genetische Erkrankung, bei der der ...
(Date:5/22/2013)... and TORONTO , May 22, 2013 ... that John Mon , Chief Operating Officer, ... on Thursday, May 30, 2013 in New York ... The Company,s presentation is scheduled to begin at 4:00 ... To access the webcast, go to:   http://wsw.com/webcast/marcum/mfs.v/   ...
Breaking Medicine Technology:Generex Announces ASCO Presentations on the Antigen Express Advanced Stage AE37 Cancer Vaccine 2Generex Announces ASCO Presentations on the Antigen Express Advanced Stage AE37 Cancer Vaccine 3Generex Announces ASCO Presentations on the Antigen Express Advanced Stage AE37 Cancer Vaccine 4Studie von Grifols zeigt, dass eine höhere Dosis von PROLASTIN-C den Alpha1-PI-Spiegel in Patienten mit AAT-Mangel in den normalen Bereich anhebt 2Studie von Grifols zeigt, dass eine höhere Dosis von PROLASTIN-C den Alpha1-PI-Spiegel in Patienten mit AAT-Mangel in den normalen Bereich anhebt 3Studie von Grifols zeigt, dass eine höhere Dosis von PROLASTIN-C den Alpha1-PI-Spiegel in Patienten mit AAT-Mangel in den normalen Bereich anhebt 4Medifocus, Inc. to Present At The Second Annual Marcum LLP MicroCap Conference 2Medifocus, Inc. to Present At The Second Annual Marcum LLP MicroCap Conference 3
... Trubion,s Proprietary ... Product Candidate, SBI-087 for RA Expands Trubion,s Family of Customized, Differentiated ... Product Candidates, ... has initiated a Phase 1/2,clinical trial of TRU-016, the company,s lead proprietary Small Modular,ImmunoPharmaceutical ...
... Encouraging Response in CF Patients - Results Validate ... March 27 The Cystic Fibrosis Foundation,announced today that ... defect in CF, showed promising results in an ongoing ... mutation of CF. The drug is,being developed by Vertex ...
Cached Medicine Technology:Trubion Initiates Phase 1/2 Study of TRU-016 in CLL, Announces Next-Generation Product Candidate for RA and Provides Product Pipeline Update 2Trubion Initiates Phase 1/2 Study of TRU-016 in CLL, Announces Next-Generation Product Candidate for RA and Provides Product Pipeline Update 3Trubion Initiates Phase 1/2 Study of TRU-016 in CLL, Announces Next-Generation Product Candidate for RA and Provides Product Pipeline Update 4Trubion Initiates Phase 1/2 Study of TRU-016 in CLL, Announces Next-Generation Product Candidate for RA and Provides Product Pipeline Update 5Cystic Fibrosis Foundation Announces Positive Early Results for Phase 2 Clinical Trial of VX-770 - an Oral Compound to Treat CF 2Cystic Fibrosis Foundation Announces Positive Early Results for Phase 2 Clinical Trial of VX-770 - an Oral Compound to Treat CF 3
Malaria Pf. Assay Range...
An immunochromatographic test for detection of 4 species of Plasmodium antigen ( P. falciparum , P. vivax , P. malariae , P. ovale ) in whole blood....
192 Test HRP-II Enzyme Immunoassay for the presence of Plasmodium falciparum infection....
Malaria device / strip (3 line, PAN-pLDH, P.f.-HRP2)...
Medicine Products: